SuppreMol

Development of new therapies for autoimmune diseases.

Launch date

Jun 2002

Employees

Market cap

Enterprise valuation

€200m (Public information from Mar 2015)

Company register number HRB 189428 B (Charlottenburg (Berlin))

Planegg Bavaria (HQ)

Revenues, earnings & profits over time

EUR	2013	2014	2015	2016	2017	2018	2019
Profit	(8.4m)	(4.7m)	(<1m)	<1m	<1m	(<1m)	(<1m)

Date	Investors	Amount	Round
Jan 2002	Max Planck Institute for Biological Intelligence Max Planck Institute of Biochemistry Max Planck Innovation Max Planck Society	N/A	Spinout
May 2006	KfW Bayern Kapital	$5.2m	Series A
Jul 2008	KfW BioMed Partners Bayern Kapital MIG Capital Santo Holding Max Planck Institute for Astronomy	€15.7m	Series B
Dec 2010	KfW BioMed Partners Bayern Kapital MIG Capital Santo Holding	€15.5m	Series C
Sep 2012	MIG Capital	€6.5m	Series D
May 2013	BioMed Partners MIG Capital Santo Holding	€9.5m	Series D
Mar 2015	Baxter International	€200m Valuation: €200m	Acquisition
Total Funding		€51.9m

Financials